文献速递肾小球疾病

HLA II类等位基因单氨基酸差异与原发性膜性肾病临床表型及结局相关

HLA class II alleles differing by a single amino acid associate with clinical phenotype and outcome in patients with primary membranous nephropathy.
PubMed 文献 · Kidney Int · 2018-08-30

该研究在258例原发性膜性肾病患者中分析HLA等位基因与临床表型及肾脏结局的关联,中位随访52个月。DRB1*0301与较高的抗PLA2R抗体水平相关,而DRB1*1502虽非易感等位基因,却与较低的eGFR、较差的肾脏结局及更高的ESRD风险相关。多因素分析显示未缓解是ESRD的唯一独立危险因素。

要点

  • DRB1*0301与较高的抗PLA2R抗体水平相关(OR 1.58)。
  • DRB1*1502与基线及末次随访eGFR较低相关,且ESRD风险升高(HR 4.52)。
  • 未缓解是ESRD的唯一独立危险因素。

核心结论

  • HLA基因调控抗PLA2R抗体产生及原发性膜性肾病的严重程度和结局。
  • DRB1*1502可能作为修饰基因,与HLA风险等位基因共存时具有强预测价值。

研究设计与样本

  • 研究纳入258例原发性膜性肾病患者,中位随访52个月,分析HLA等位基因与 demographic 特征、抗PLA2R抗体、治疗反应及肾脏结局的关联。

主要发现

  • DRB1*0301与较高的抗PLA2R抗体水平显著相关(OR 1.58,95%CI 1.13-2.22)。
  • DRB1*1502与基线eGFR较低显著相关(OR 1.79,95%CI 1.18-2.72),与末次随访eGFR较低显著相关(OR 1.72,95%CI 1.17-2.53)。
  • Kaplan-Meier分析显示DRB1*1502与显著较差的肾脏结局相关,Cox回归显示其与ESRD风险显著升高相关(HR 4.52,95%CI 1.22-16.74)。
  • 多因素分析显示未缓解是ESRD的唯一独立危险因素。
  • DRB1*1502与显著较高的中位抗PLA2R抗体水平相关(161.4 vs. 36.3 U/mL),并与DRB1*0301存在交互作用。

临床怎么用

  • 对原发性膜性肾病患者可考虑HLA分型以辅助风险评估。
  • 携带DRB1*1502者需更密切监测肾功能和抗PLA2R抗体水平。
  • 治疗应致力于实现缓解以降低ESRD风险。

局限性

  • 其他修饰基因需在更大队列中进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Genome-wide associations and HLA genotyping have revealed associations between HLA alleles and susceptibility to primary membranous nephropathy. However, associations with clinical phenotypes and kidney outcome are poorly defined. We previously identified DRB1*1501 and DRB1*0301 as independent risk alleles for primary membranous nephropathy. Here, we investigated HLA associations with demographic characteristics, anti-phospholipase A2 receptor (PLA2R) antibody, treatment response and kidney outcome after a median follow-up of 52 months in 258 patients. DRB1*0301, but not DRB1*1501, was associated with a significantly higher level of PLA2R antibody (odds ratio 1.58, 95% confidence interval 1.13-2.22). Although DRB1*1502, which differs from DRB1*1501 by a single amino acid, was not a risk allele for primary membranous nephropathy (odds ratio 1.01), it was associated with significantly lower estimated glomerular filtration rates both at baseline (1.79, 1.18-2.72) and at last follow-up (1.72, 1.17-2.53), a significantly worse renal outcome by Kaplan-Meier analysis and a significantly higher risk of end-stage renal disease by Cox regression analysis (hazard ratio 4.52, 1.22-16.74). Nevertheless, the absence of remission remained the only independent risk factor for end-stage renal disease by multivariate analysis. DRB1*1502 was also associated with a significantly higher median PLA2R antibody level [161.4 vs. 36.3 U/mL] and showed interaction with DRB1*0301 for this variable. Thus, HLA genes control PLA2R antibody production and primary membranous nephropathy severity and outcome. Additionally, DRB1*1502 behaves like a modifier gene with a strong predictor value when associated with HLA risk alleles. Other modifier genes need further investigations in larger cohorts.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Wang HY, Cui Z, Xie LJ, et al. HLA class II alleles differing by a single amino acid associate with clinical phenotype and outcome in patients with primary membranous nephropathy. Kidney Int. 2018. PMID: 30173899. doi:10.1016/j.kint.2018.06.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。